Navigation Links
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Date:5/28/2008

Patients with Adenocarcinoma or Large Cell Carcinoma Histologies Achieved Improvement in Overall Survival when Treated with ALIMTA-based Regimen

INDIANAPOLIS, May 28 /PRNewswire-FirstCall/ -- The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published online in the Journal of Clinical Oncology. Publication of the study was announced by Eli Lilly and Company.

The 1,725-patient study, the largest Phase III clinical trial in the first-line NSCLC setting, evaluated ALIMTA(R) (pemetrexed for injection) plus cisplatin versus GEMZAR(R) (gemcitabine HCl for injection) plus cisplatin, a standard of treatment in this setting. The trial met its primary endpoint of non-inferiority relative to overall survival.

Additionally, in a pre-planned histological analysis, patients with either adenocarcinoma or large-cell carcinoma had a statistically superior and clinically relevant improvement in overall survival when treated with the pemetrexed regimen in the first-line setting.

In comparison, patients with squamous cell histology were found to have a more favorable overall survival when treated with the gemcitabine regimen.

"While non-small cell lung cancer has typically been treated as one disease, this study confirms that histology, or tumor type, can provide a clue as to which treatment regimen works best for a particular tumor type," said the study's lead author, Giorgio Scagliotti, M.D., Department of Clinical and Biological Sciences Thoracic Oncology Unit, University of Torino, Orbassano, Italy. "If we can tailor the therapy for better results, we are closer to improving outcomes for this terrible disease."

The overall survival of patients treated with either the pemetrexed regimen or gemcitabine regimen was found to be non-inferior, with a median survival of 10.3 months. However, when researchers reviewed
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Global study reveals differences in standard of care for osteoporosis across the world
2. New study shows positive role physical therapists play in lymphedema diagnois and treatment
3. RTOG Study Likely Treatment Option for Brain Tumor Patients like Sen. Kennedy
4. New CDC Study Shows Smoke-Free Laws Spreading Across U.S. and Should Spur Remaining States to Take Action
5. Experimental agent blocks prostate cancer in animal study
6. Study finds unique HIV vaccine formula elicits strong immune responses
7. First of its kind study compares high school knee injuries by sport and gender
8. UNC study firms up promise of potential new cervical cancer screening tool
9. Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
10. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
11. Israeli study finds obstructive sleep apnea is health factor from day 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Don Allred Insurance, ... health insurance plans for North Carolina residents, is excited ... in Burlington’s Holly Hill Mall. The new branch has ... already helping customers through all facets of the insurance ... Allred Insurance spokesman Scott Allred couldn’t be happier with ...
(Date:10/30/2014)... OR (PRWEB) October 30, 2014 Five ... firm Hodgkinson Street LLC announces new branding and ... Hodgkinson Street Mepham . After David Mepham’s promotion to ... their brand and website to include Mepham’s name and ... medical malpractice and mediation firm, the decision to implement ...
(Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter ... hormone therapy to men with prostate cancer who also have ... a heart-related cause, a new study suggests. , , The therapy ... in prostate cancer to reduce levels of male hormones to ... And, in the current research, this hormone therapy was linked ...
(Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... study conducted by the University of Erfurt in Erfurt, ... inflict financial pain to achieve// collective gain. The study ... ,Researchers have found that groups in which individual ... popular than groups without this option. Though two thirds ...
... theme park people have come together to set up an ... from the Himalayan expedition to China and Nepal. They ... previously unknown to science. This was brought about by the ... a giant hornet which the local address as the Yak ...
... The drug Macugen was approved by the Food and ... as macular degeneration was reported// to show serious allergic ... use of their eye drug Macugen along with other ... companies have already notified the doctors about the reactions, ...
... a reassuring announcement that will bring hope to those people ... to be instituted, the government will realize its target of ... next two months. This will indeed provide a renewed thrust ... ,In the words of Anbumani Ramadoss “In another two ...
... Association (IMA),secretary of Ranchi, speaking for World Health ... all segments including doctors//, nurses, paramedics, laboratory technicians, ... society. ,The IMA secretary, Ajay Kumar ... healthcare, rather the cooperation of all healthcare segments ...
... with a new neupro skin patch which is offered the ... offer relief to patients// in the early stages of Parkinson's ... a naturally occurring brain chemical, which is in short supply ... said that the patch would aid the patients to manage ...
Cached Medicine News:Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 2Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 3Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 4
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
(Date:10/30/2014)... 30, 2014 , Extensively hydrolyzed ... milk   Cow milk protein allergy (CMPA) is the leading ... Until now, it has been managed by eliminating milk ... shown that it is possible to help build of ... of children during the first year of life by ...
(Date:10/30/2014)... LONDON , Oct. 29, 2014 ... electrical potential which can be amplified to diagnose ... The electrodes used in medical devices facilitate the ... obtained from muscle cells and neurons of the ... electrodes utilize the radiofrequency alternating current to perform ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
... -- ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" ... research and development outsourcing company, today announced that it ... in its biologics division, which portends strong growth for ... milestones were achieved for two oncology projects that are ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: ... the pharmaceutical, biotechnology, and medical device industries, with operations in ... for the second quarter of 2011. Highlights ... Million for the First Time Second-Quarter 2011 Net ...
Cached Medicine Technology:ShangPharma's Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects 2WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Straight shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: